Teva’s thrice-weekly 40mg Copaxone will (if approved) be a distinct branded drug from regular Copaxone (which is dosed 20mg qD). Hence, thrice-weekly Copaxone will not be substitutable when a prescription is written for regular Copaxone.
Prescriptions written for thrice-weekly Copaxone could cannibalize sales of regular Copaxone to some degree if neuros actually think it a better product, but I would expect such cannibalization to be relatively small given the longstanding safety record of regular Copaxone.
p.s. Thrice-weekly Copaxone has no effect on the Copaxone patent litigation between Teva, NVS/MNTA, and MYL.
News 
Market Data 
Discover 
AI
